Roth Capital Markets started coverage on the stock at a “Buy” rating. Joe Pantiginis set the target price of the stock at $3 and cited the company’s commitment to focus on cancer drugs as a reason for the positive rating. He noted that after multiple transition years, Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) could be on the cusp of a crucial year in which it could report critical data on several drug candidates. Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) stock opened at $0.94 in last trading session, and closed at $1.00, trading in the range of $0.87 – $1.05. The stock showed a positive/negative weekly performance of -10.71%.
TheStreet reissued their positive rating on shares of Gilead Sciences (NASDAQ:GILD) in a research note released on Wednesday morning, Stock Ratings Network reports. Gilead Sciences, Inc. (NASDAQ:GILD) shares closed at $80.62 on last trade day, by losing -1.86%. Stock 52 week range is $38.54 – $84.40. Company’s market capitalization is $123.62 billion.
Hemispherx BioPharma, Inc (NYSEMKT:HEB), announced that Dr. William M. Mitchell of Vanderbilt University presented a research paper on January 21, 2014 at the Keystone Symposia Conference on Pathogenesis of Respiratory Viruses entitled “Protection from Pulmonary Tissue Damage Associated with Infection of Cynomolgus Macaques by Highly Pathogenic Avian Influenza Virus (H5N1) by Low Dose Natural Human IFN-α Administered to the Buccal Mucosa.” This presentation is a collaborative project conducted at Viroclinics, Rotterdam, an internationally recognized research entity for the study of both seasonal and pandemic influenza viruses. Hemispherx BioPharma, Inc (NYSEMKT:HEB) stock decreased -7.27% and finished the last session at $0.510. The EPS of the stock remained -0.13. Company’s market capitalization is $85.52 billion.
Exelixis, Inc. (NASDAQ:EXEL) announced the pricing of its overnight underwritten public offering of 10,000,000 shares of newly issued common stock at a price to the public of $8.00 per share. Exelixis also granted the underwriter a 30-day option to purchase up to an additional 1,500,000 shares of common stock in connection with the offering. All of the shares of common stock in the offering are being sold by Exelixis. Exelixis anticipates that its aggregate net proceeds from the offering will be $75.6 million after deducting the underwriting discount and estimated offering expenses payable by Exelixis (assuming no exercise of the underwriter’s option to purchase additional shares). Exelixis, Inc. (NASDAQ:EXEL) stock opened at $7.94 in last trading session and closed at $7.64. The 52 week range of the stock is $4.32 – $8.41 and the day range was $7.62 – $8.09.